Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

Completed · Phase 3 · Has a placebo group

Conditions studied: GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome

In brief

The study objective is to compare the efficacy and safety of US-ATG-F as a supplement to standard of care prophylaxis versus standard of care prophylaxis alone in moderate to severe chronic GVHD-free survival.

Key facts

Study ID
NCT01295710
Run by
Neovii Biotech
People needed
260
Starts
2011-10-10
Expected to finish
2015-10-15
Last updated by the study team
2019-04-09

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.